{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:19:25Z","timestamp":1787987965360,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"DOI":"10.1007\/s00428-026-04706-9","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:37:25Z","timestamp":1787985445000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic reproducibility, spatial heterogeneity, and survival outcomes of HER2-Null, HER2-Ultralow, and HER2-Low categories in invasive breast carcinoma"],"prefix":"10.1007","author":[{"given":"Rabia","family":"Hursitoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkadir Yasir","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda Keskin","family":"Gokmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhan","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ummu Gulsum","family":"Sarac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Turanciftci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"issue":"3","key":"4706_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 74(3):229\u2013263","journal-title":"Cancer J Clin"},{"issue":"10087","key":"4706_CR2","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni L (2017) HER2-positive breast cancer. Lancet 389(10087):2415\u20132429","journal-title":"Lancet"},{"issue":"2","key":"4706_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E (2023) Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discovery 22(2):101\u2013126","journal-title":"Nat Rev Drug Discovery"},{"issue":"5","key":"4706_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3322\/caac.21634","volume":"70","author":"GM Choong","year":"2020","unstructured":"Choong GM, Cullen GD, O\u2019Sullivan CC (2020) Evolving standards of care and new challenges in the management of HER2-positive breast cancer. Cancer J Clin 70(5):355\u2013374","journal-title":"Cancer J Clin"},{"issue":"22","key":"4706_CR5","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM et al (2023) Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013College of American Pathologists Guideline Update. J Clin Oncol 41(22):3867\u20133872","journal-title":"J Clin Oncol"},{"issue":"1","key":"4706_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9\u201320","journal-title":"N Engl J Med"},{"issue":"24","key":"4706_CR7","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.3390\/cancers17244021","volume":"17","author":"NA Bagegni","year":"2025","unstructured":"Bagegni NA, Giridhar KV, Stewart D (2025) HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers. Cancers 17(24):4021","journal-title":"Cancers"},{"issue":"3","key":"4706_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10549-024-07336-4","volume":"206","author":"M Corian\u00f2","year":"2024","unstructured":"Corian\u00f2 M, Tommasi C, Dinh ATL, Needham J, Aziz H, Joharatnam-Hogan N et al (2024) The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study. Breast Cancer Res Treat 206(3):603\u2013614","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4706_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10549-021-06365-7","volume":"190","author":"L de Moura Leite","year":"2021","unstructured":"de Moura Leite L, Cesca MG, Tavares MC, Santana DM, Saldanha EF, Guimar\u00e3es PT et al (2021) HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Res Treat 190(1):155\u2013163","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"4706_CR10","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/jamaoncol.2022.1922","volume":"8","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J et al (2022) Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol 8(8):1177\u20131183","journal-title":"JAMA Oncol"},{"key":"4706_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13058-024-01899-2","volume":"26","author":"G Nader-Marta","year":"2024","unstructured":"Nader-Marta G, Singer C, Hlauschek D, DeMichele A, Tarantino P, de Azambuja E et al (2024) Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42\/AFT-05\/BIG-14\u201313\/PrE0109). Breast cancer research: BCR 26:140","journal-title":"Breast cancer research: BCR"},{"key":"4706_CR12","doi-asserted-by":"publisher","unstructured":"Rakha EA, Tan PH, Van Bockstal MR, Allison KH, Brogi E, Callagy G et al (2026) International expert consensus recommendations for HER2 reporting in breast cancer: focus on HER2-low and ultralow categories. Mod Pathol 39(1):100925. https:\/\/doi.org\/10.1016\/j.modpat.2025.100925","DOI":"10.1016\/j.modpat.2025.100925"},{"key":"4706_CR13","doi-asserted-by":"publisher","first-page":"152288","DOI":"10.1016\/j.anndiagpath.2024.152288","volume":"70","author":"J Wang","year":"2024","unstructured":"Wang J, Yoon E, Krishnamurthy S (2024) Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry. Annals Diagn Pathol 70:152288","journal-title":"Annals Diagn Pathol"},{"key":"4706_CR14","doi-asserted-by":"publisher","unstructured":"Li M, Cai MY, Lv H et al (2026) Illuminating the clinicopathological and genomic landscape of HER2-null, ultralow, and low breast cancers: insights into diagnostic discordance between biopsy and surgical excision. npj Breast Cancer 12:17. https:\/\/doi.org\/10.1038\/s41523-025-00882-0","DOI":"10.1038\/s41523-025-00882-0"},{"issue":"1","key":"4706_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13058-025-02001-0","volume":"27","author":"H Lv","year":"2025","unstructured":"Lv H, Yue J, Zhang Q, Xu F, Gao P, Yang H et al (2025) Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China. Breast Cancer Res 27(1):45","journal-title":"Breast Cancer Res"},{"issue":"4","key":"4706_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1634\/theoncologist.2016-0352","volume":"22","author":"YJ Shi","year":"2017","unstructured":"Shi YJ, Tsang JY, Ni YB, Tse GM (2017) Intratumoral Heterogeneity in Breast Cancer: A Comparison of Primary and Metastatic Breast Cancers. Oncologist 22(4):487\u2013490 PubMed PMID: 28341760. Pubmed Central PMCID: PMC5388387. Epub 2017\/03\/28. eng","journal-title":"Oncologist"},{"issue":"10","key":"4706_CR17","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3390\/cancers15102664","volume":"15","author":"Y Hou","year":"2023","unstructured":"Hou Y, Nitta H, Li Z (2023) HER2 intratumoral heterogeneity in breast cancer, an evolving concept. Cancers 15(10):2664","journal-title":"Cancers"},{"key":"4706_CR18","doi-asserted-by":"crossref","unstructured":"Beca F, Polyak K (2016) Intratumor heterogeneity in breast cancer. Novel biomarkers in the continuum of breast cancer. Springer, pp 169\u2013189","DOI":"10.1007\/978-3-319-22909-6_7"},{"issue":"5","key":"4706_CR19","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/ajcp\/aqac184","volume":"159","author":"C Karakas","year":"2023","unstructured":"Karakas C, Tyburski H, Turner BM, Wang X, Schiffhauer LM, Katerji H et al (2023) Interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low\u2013expressing breast cancer cohort. Am J Clin Pathol 159(5):484\u2013491","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"4706_CR20","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1001\/jamaoncol.2021.7239","volume":"8","author":"AI Fernandez","year":"2022","unstructured":"Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K et al (2022) Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol 8(4):607\u2013610","journal-title":"JAMA Oncol"},{"issue":"2","key":"4706_CR21","doi-asserted-by":"publisher","first-page":"104127","DOI":"10.1016\/j.esmoop.2024.104127","volume":"10","author":"S Wu","year":"2025","unstructured":"Wu S, Shang J, Li Z, Liu H, Xu X, Zhang Z et al (2025) Interobserver consistency and diagnostic challenges in HER2-ultralow breast cancer: a multicenter study. ESMO open 10(2):104127","journal-title":"ESMO open"},{"issue":"1","key":"4706_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00428-023-03656-w","volume":"484","author":"M Ivanova","year":"2024","unstructured":"Ivanova M, Porta FM, D\u2019Ercole M, Pescia C, Sajjadi E, Cursano G et al (2024) Standardized pathology report for HER2 testing in compliance with 2023 ASCO\/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Arch 484(1):3\u201314","journal-title":"Virchows Arch"},{"issue":"5","key":"4706_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.5858\/arpa.2024-0052-OA","volume":"149","author":"J R\u00fcschoff","year":"2025","unstructured":"R\u00fcschoff J, Penner A, Ellis IO, Hammond MEH, Lebeau A, Osamura RY et al (2025) Global study on the accuracy of human epidermal growth factor receptor 2-low diagnosis in breast cancer. Arch Pathol Lab Med 149(5):431\u2013438","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"4706_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13000-025-01624-3","volume":"20","author":"A Wr\u00f3bel","year":"2025","unstructured":"Wr\u00f3bel A, Vandenberghe M, Scott M, Jones F, Matsuo T, Boothman A-M et al (2025) Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff: HER2 IHC scoring concordance in breast cancer. Diagn Pathol 20(1):35","journal-title":"Diagn Pathol"},{"issue":"1","key":"4706_CR25","doi-asserted-by":"publisher","first-page":"12129","DOI":"10.1038\/s41598-024-61957-9","volume":"14","author":"A Kapil","year":"2024","unstructured":"Kapil A, Spitzm\u00fcller A, Brieu N, Haneder S, Shumilov A, Meier A et al (2024) HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer. Sci Rep 14(1):12129","journal-title":"Sci Rep"},{"key":"4706_CR26","doi-asserted-by":"publisher","unstructured":"Wu S, Liu H, Wang T, Miao J, Zhuan J, Cui Z, Yue M, Wang K, Li J, Han M, Hu W, Wang X, Liu Y (2025) HER2 testing in multifocal\/multicentric breast cancer: should all foci be tested in the context of HER2-low and HER2-ultralow? Breast 84:104572. https:\/\/doi.org\/10.1016\/j.breast.2025.104572","DOI":"10.1016\/j.breast.2025.104572"},{"issue":"6","key":"4706_CR27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/cncr.35101","volume":"130","author":"M Lin","year":"2024","unstructured":"Lin M, Luo T, Jin Y, Zhong X, Zheng D, Zeng C et al (2024) HER2-low heterogeneity between primary and paired recurrent\/metastatic breast cancer: Implications in treatment and prognosis. Cancer 130(6):851\u2013862","journal-title":"Cancer"},{"issue":"3","key":"4706_CR28","doi-asserted-by":"publisher","first-page":"e70269","DOI":"10.1002\/cncr.70269","volume":"132","author":"Y Qiu","year":"2026","unstructured":"Qiu Y, Wu L, Cai W, Chen M, Jiang M, Wang Y et al (2026) The evolution and prognostic impact of HER2-low, HER2\u2010ultralow, and HER2\u2010null status in HER2\u2010negative early breast cancer: A pre\u2013to post\u2013neoadjuvant chemotherapy study. Cancer 132(3):e70269","journal-title":"Cancer"},{"key":"4706_CR29","doi-asserted-by":"publisher","unstructured":"Tiwary A, Francis SS, Sharma S et al (2026) Clinicopathological characteristics across the HER2 expression spectrum in invasive breast carcinoma of no special type: a single-centre retrospective study. Diagn Pathol 21:57. https:\/\/doi.org\/10.1186\/s13000-026-01791-x","DOI":"10.1186\/s13000-026-01791-x"},{"issue":"4","key":"4706_CR30","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3390\/medicina61040719","volume":"61","author":"S Akay","year":"2025","unstructured":"Akay S, Emiroglu M, Kelten Talu C, Unal OU (2025) Comparison of clinicopathological characteristics for HER2-null, HER2-ultralow and HER2-low breast cancer: a single-center study. Medicina 61(4):719","journal-title":"Medicina"},{"issue":"2","key":"4706_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10549-023-07079-8","volume":"202","author":"Z Chen","year":"2023","unstructured":"Chen Z, Jia H, Zhang H, Chen L, Zhao P, Zhao J et al (2023) Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Res Treat 202(2):313\u2013323","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"4706_CR32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.clbc.2024.02.013","volume":"24","author":"R Nishimura","year":"2024","unstructured":"Nishimura R, Fujiki Y, Taira T, Miyaki T, Kanemitsu S, Yotsumoto D et al (2024) The clinicopathological and prognostic significance of HER2-Low breast cancer: a comparative analysis between HER2-Low and HER2-Zero subtypes. Clin Breast Cancer 24(5):431\u2013438","journal-title":"Clin Breast Cancer"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04706-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-026-04706-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04706-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:37:27Z","timestamp":1787985447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-026-04706-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":32,"alternative-id":["4706"],"URL":"https:\/\/doi.org\/10.1007\/s00428-026-04706-9","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Institutional Ethics Committee of Kahramanmaras Sutcu Imam University, Faculty of Medicine (Approval Date: April 20, 2026; Approval Number: 08). Due to the retrospective nature of the study, the requirement for informed consent was waived by the ethics committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any identifying patient information or images.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}